SLU-PP-332 Australia: Exercise Mimetic Research Compound Guide

SLU-PP-332 is a synthetic small-molecule agonist of ERRα (Estrogen-Related Receptor alpha), a nuclear receptor that regulates mitochondrial biogenesis, oxidative metabolism, and the transcriptional signature of endurance exercise in skeletal muscle. It was developed by researchers at Scripps Research (La Jolla, California) and published in Nature Communications in 2023 (Flynn et al.).

ERRα sits upstream of PGC-1α, the master regulator of mitochondrial biogenesis, and coordinates expression of genes involved in fatty acid oxidation, oxidative phosphorylation, and slow-twitch (Type I) muscle fibre development. By activating ERRα directly, SLU-PP-332 drives these pathways without requiring the mechanical or metabolic stress of physical exercise, making it one of the most researched "exercise mimetic" compounds in recent preclinical literature.

SLU-PP-332 is a research compound with no TGA-approved therapeutic applications. It is distinct from peptide-based exercise mimetics (such as AICAR or GW501516) and operates via nuclear receptor pharmacology rather than kinase signalling. For research use only.

ERRα (NR3B1) is an orphan nuclear receptor, meaning it lacks a known endogenous ligand, expressed highly in tissues with elevated energy demand: skeletal muscle, heart, kidney, and brown adipose tissue. Under conditions of endurance exercise, PGC-1α is upregulated and co-activates ERRα, driving a coordinated transcriptional response that increases mitochondrial density, shifts muscle fibre composition toward oxidative types, and enhances fatty acid oxidation capacity.

SLU-PP-332 acts as a direct ERRα agonist, binding the receptor's ligand-binding domain and activating this transcriptional programme pharmacologically. Key downstream effects documented in preclinical research include:

• Mitochondrial biogenesis, upregulation of PGC-1α, TFAM, and cytochrome c oxidase subunits, increasing mitochondrial number and oxidative capacity in skeletal muscle
• Fatty acid oxidation, increased expression of CPT1 and ACADM, key enzymes in mitochondrial fatty acid import and β-oxidation
• Muscle fibre remodelling, shift toward Type I (slow-twitch, oxidative) fibre gene expression, associated with improved endurance capacity
• Metabolic rate, increased whole-body oxygen consumption in treated animals, consistent with elevated mitochondrial activity

Unlike AMPK activators (AICAR) or PPARδ agonists (GW501516), SLU-PP-332 operates at the level of a nuclear transcription factor rather than a kinase signalling cascade, potentially providing a more direct and selective activation of the endurance exercise transcriptome.

The pivotal preclinical study by Flynn et al. (2023), published in Nature Communications, evaluated SLU-PP-332 in sedentary mice over a four-week treatment period. Key findings included:

• ~70% improvement in treadmill endurance, treated mice ran significantly further to exhaustion compared to vehicle controls, without any exercise training during the study period
• Increased mitochondrial gene expression, skeletal muscle biopsies showed upregulation of ERRα target genes consistent with the endurance exercise transcriptome
• Improved metabolic parameters, treated animals showed reduced weight gain and improved metabolic efficiency on a high-fat diet protocol
• Cardiac effects, ERRα activation in cardiac tissue was also observed, with gene expression changes consistent with improved cardiac oxidative metabolism

The study positioned SLU-PP-332 as the first pharmacological agent to demonstrate endurance improvement in sedentary animals purely through nuclear receptor pharmacology, without the cardiovascular or off-target effects associated with earlier exercise mimetic candidates such as GW501516.

No human clinical trials of SLU-PP-332 have been conducted as of 2026. All published evidence is from animal models and in-vitro studies.

The exercise mimetic field has attracted significant research interest due to the potential for pharmacological activation of exercise-induced metabolic pathways in populations unable to perform physical activity, including patients with muscle wasting, mobility limitations, metabolic syndrome, or type 2 diabetes.

SLU-PP-332 is one of several ERR-targeting compounds under investigation. Earlier exercise mimetics (GW501516/Cardarine, AICAR) demonstrated efficacy in preclinical models but carried concerns around off-target effects. SLU-PP-332's ERRα selectivity profile has been cited as an advantage in the research literature, though long-term safety data in any species remains limited.

Research applications being investigated include:

• Skeletal muscle metabolism and atrophy models
• Obesity and diet-induced metabolic dysfunction
• Cardiac metabolism and heart failure models
• Sarcopenia (age-related muscle loss)
• Mitochondrial disease models

SLU-PP-332 is a research compound available from specialised Australian research peptide suppliers. As a small molecule (not a peptide), it is typically supplied as a lyophilised powder or in solution form, with a Certificate of Analysis (COA) confirming identity and purity via HPLC and mass spectrometry.

When sourcing SLU-PP-332 for laboratory research, verify: (1) COA from a third-party analytical laboratory; (2) purity ≥98% by HPLC; (3) identity confirmed by mass spectrometry matching the published molecular weight of 395.47 g/mol (CAS: 2070014-87-6).

SLU-PP-332 is supplied for in-vitro laboratory and preclinical research use only. It is not approved for human or animal therapeutic use in Australia. For research use only.

SLU-PP-332 is sold strictly for in-vitro laboratory and scientific research purposes only. Not TGA-approved. Not for human or animal administration. OzPeps supplies research compounds to researchers and laboratory professionals for authorised research use only.